Managing Asthma in Adolescents and Adults

Abstract

IMPORTANCEAsthma is a major public health problem worldwide and is associated with excess morbidity, mortality, and economic costs associated with lost productivity. The National Asthma Education and Prevention Program has released the 2020 Asthma Guideline Update with updated evidence-based recommendations for treatment of patients with asthma.OBJECTIVE To report updated recommendations for 6 topics for clinical management of adolescents and adults with asthma: (1) intermittent inhaled corticosteroids (ICSs); (2) add-on long-acting muscarinic antagonists; (3) fractional exhaled nitric oxide; (4) indoor allergen mitigation; (5) immunotherapy; and (6) bronchial thermoplasty. EVIDENCE REVIEWThe National Heart, Lung, and Blood Advisory Council chose 6 topics to update the 2007 asthma guidelines based on results from a 2014 needs assessment. The Agency for Healthcare Research and Quality conducted systematic reviews of these 6 topics based on literature searches up to March-April 2017. Reviews were updated through October 2018 and used by an expert panel (n = 19) that included asthma content experts, primary care clinicians, dissemination and implementation experts, and health policy experts to develop 19 new recommendations using the GRADE method. The 17 recommendations for individuals aged 12 years or older are reported in this Special Communication.FINDINGS From 20 572 identified references, 475 were included in the 6 systematic reviews to form the evidence basis for these recommendations. Compared with the 2007 guideline, there was no recommended change in step 1 (intermittent asthma) therapy (as-needed short-acting β 2 -agonists [SABAs] for rescue therapy). In step 2 (mild persistent asthma), either daily low-dose ICS plus as-needed SABA therapy or as-needed concomitant ICS and SABA therapy are recommended. Formoterol in combination with an ICS in a single inhaler (single maintenance and reliever therapy) is recommended as the preferred therapy for moderate persistent asthma in step 3 (low-dose ICS-formoterol therapy) and step 4 (medium-dose ICS-formoterol therapy) for both daily and as-needed therapy. A short-term increase in the ICS dose alone for worsening of asthma symptoms is not recommended. Add-on long-acting muscarinic antagonists are recommended in individuals whose asthma is not controlled by ICS-formoterol therapy for step 5 (moderate-severe persistent asthma). Fractional exhaled nitric oxide testing is recommended to assist in diagnosis and monitoring of symptoms, but not alone to diagnose or monitor asthma. Allergen mitigation is recommended only in individuals with exposure and relevant sensitivity or symptoms. When used, allergen mitigation should be allergen specific and include multiple allergen-specific mitigation strategies. Subcutaneous immunotherapy is recommended as an adjunct to standard pharmacotherapy for individuals with symptoms and sensitization to specific allergens. Sublingual immunotherapy is not recommended specifically for asthma. Bronchial thermoplasty is not recommended as part...

An Overview of Asthma and COVID-19: Protective Factors Against SARS-COV-2 in Pediatric Patients

“…These effects are reinforced when glycopyrronium is used in combination with formoterol and budesonide in vitro ( 27 , 37 ). Nonetheless, glycopirronium is not routinely used in children and more studies are needed to better understand if asthma treatment could really be considered protective against SARS-COV-2 infection ( 27 , 51 ).…”

Inhaled long-acting muscarinic antagonists in asthma – A narrative review

“…Recently, LAMAs, initially tiotropium, later glycopyrronium and umeclidinium, have been studied as add-on therapy in patients with asthma, and particularly in patients who have persistent asthma symptoms or exacerbations despite optimised inhaled corticosteroid (ICS)/ LABA treatment [7]. Indeed, both the Global Initiative for Asthma (GINA) strategy document and the National Asthma Education and Prevention Program guideline position tiotropium before biologic drugs or oral corticosteroids (OCS) [10,11]. In addition, the European Respiratory Society (ERS)/American Thoracic Society (ATS) Severe Asthma Task Force recommends tiotropium as an add-on to ICS/LABA in patients with severe asthma regardless of phenotype [12].…”

Emerging Cell-Based Therapies in Chronic Lung Diseases: What About Asthma?

“…However, only SLIT showed clinical improvement related to Tregs (Xian et al, 2020). Despite these results, SCIT is just recommended as an adjunct to pharmacotherapy in individuals with asthma, and SLIT is not recommended (Cloutier et al, 2020).…”